In ordering the additional discovery, U.S. District Judge Nina Gershon pointed out that McKesson—represented by Covington & Burling—had told U.S. Magistrate Judge Steven Tiscione “in the strongest ...

McKesson (NYSE:MCK) has outperformed the market over the past 5 years by 21.85% on an annualized basis producing an average annual return of 34.98%. Currently, McKesson has a market capitalization of ...

Curious if McKesson is currently a bargain, or if the impressive run has left little value on the table? Let’s explore what is influencing opinions on its price and consider the factors that may shape ...

Nov 5 (Reuters) - Drug distributor McKesson (MCK.N), opens new tab raised its fiscal 2026 profit forecast on Wednesday, betting on strong growth in its oncology and specialty drug distribution ...

Healthcare distributor and services company McKesson (NYSE:MCK) will be reporting earnings this Wednesday afternoon. Here’s what investors should know. McKesson beat analysts’ revenue expectations by ...

A $152.3 million judgment accepted by Baltimore City in an opioid lawsuit against pharmaceutical companies McKesson and Cencora could be overturned after McKesson filed an appeal. The appeal was filed ...

McKesson MCK0.02%increase; green up pointing triangle updated its targets for fiscal 2026 and beyond as the diversified healthcare services company continues to advance its growth strategy. The ...

When trying to connect to a WiFi network, either managed by your company, school, or some other organization, using the provided credentials, we failed to make the ...

Deal Rationale McKesson’s strategic focus on disciplined portfolio management involves continuous evaluation of its business segments to ensure alignment with its growth priorities and optimize ...

McKesson has consistently grown ahead of the broader market in recent years. The stock’s steady earnings should attract safety-minded investors in the current climate. Margins could edge higher as the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It's the second major ...

McKesson Corporation has signed a definitive agreement to acquire an 80% stake in Prism Vision Holdings from Quad-C for approximately $850 million. The acquisition will enable Prism, an ophthalmology ...